JP4091436B2 - 抗炎症活性および抗アテローム生成活性を示すカワミドリ抽出物およびそれから単離され、精製されたチリアニンを含有する組成物 - Google Patents
抗炎症活性および抗アテローム生成活性を示すカワミドリ抽出物およびそれから単離され、精製されたチリアニンを含有する組成物 Download PDFInfo
- Publication number
- JP4091436B2 JP4091436B2 JP2002573027A JP2002573027A JP4091436B2 JP 4091436 B2 JP4091436 B2 JP 4091436B2 JP 2002573027 A JP2002573027 A JP 2002573027A JP 2002573027 A JP2002573027 A JP 2002573027A JP 4091436 B2 JP4091436 B2 JP 4091436B2
- Authority
- JP
- Japan
- Prior art keywords
- activity
- kawamidori
- extract
- inflammatory
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000284 extract Substances 0.000 title claims description 74
- 230000003110 anti-inflammatory effect Effects 0.000 title description 13
- 239000000203 mixture Substances 0.000 title description 8
- 230000001747 exhibiting effect Effects 0.000 title description 2
- 230000000489 anti-atherogenic effect Effects 0.000 title 1
- 206010061218 Inflammation Diseases 0.000 claims description 14
- 230000004054 inflammatory process Effects 0.000 claims description 14
- 201000001320 Atherosclerosis Diseases 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- NLZCOTZRUWYPTP-MIUGBVLSSA-N 5-hydroxy-2-(4-methoxyphenyl)-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one Chemical compound C1=CC(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NLZCOTZRUWYPTP-MIUGBVLSSA-N 0.000 claims description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 8
- NLZCOTZRUWYPTP-UHFFFAOYSA-N acacetin-7-O-beta-D-galactoside Natural products C1=CC(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2OC1C(O)C(O)C(O)C(CO)O1 NLZCOTZRUWYPTP-UHFFFAOYSA-N 0.000 claims description 8
- GWOKWCRSUJQOMD-UHFFFAOYSA-N tilianin Natural products C1=CC(OC)=CC=C1C(OC1=C2)=CC(=O)C1=CC=C2OC1C(O)C(O)C(O)C(CO)O1 GWOKWCRSUJQOMD-UHFFFAOYSA-N 0.000 claims description 8
- 240000004510 Agastache rugosa Species 0.000 claims description 3
- 235000010686 Agastache rugosa Nutrition 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 43
- 230000003902 lesion Effects 0.000 description 39
- 230000002401 inhibitory effect Effects 0.000 description 37
- 210000004027 cell Anatomy 0.000 description 32
- 230000000694 effects Effects 0.000 description 26
- 238000000034 method Methods 0.000 description 26
- 238000004519 manufacturing process Methods 0.000 description 18
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 17
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 17
- 239000000523 sample Substances 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 14
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 14
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 14
- 230000008569 process Effects 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 239000002953 phosphate buffered saline Substances 0.000 description 12
- 210000002540 macrophage Anatomy 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 230000002391 anti-complement effect Effects 0.000 description 10
- 108010008730 anticomplement Proteins 0.000 description 10
- 230000003143 atherosclerotic effect Effects 0.000 description 10
- 235000005911 diet Nutrition 0.000 description 10
- 230000037213 diet Effects 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 230000002757 inflammatory effect Effects 0.000 description 10
- 230000028709 inflammatory response Effects 0.000 description 10
- 238000011161 development Methods 0.000 description 8
- 239000002158 endotoxin Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 229920006008 lipopolysaccharide Polymers 0.000 description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 238000010171 animal model Methods 0.000 description 7
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 7
- 210000001367 artery Anatomy 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000000679 carrageenan Substances 0.000 description 7
- 229920001525 carrageenan Polymers 0.000 description 7
- 235000010418 carrageenan Nutrition 0.000 description 7
- 229940113118 carrageenan Drugs 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 210000002889 endothelial cell Anatomy 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000002036 chloroform fraction Substances 0.000 description 6
- 210000002865 immune cell Anatomy 0.000 description 6
- 210000004969 inflammatory cell Anatomy 0.000 description 6
- 210000001616 monocyte Anatomy 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 102000007330 LDL Lipoproteins Human genes 0.000 description 5
- 108010007622 LDL Lipoproteins Proteins 0.000 description 5
- 210000001765 aortic valve Anatomy 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000002034 butanolic fraction Substances 0.000 description 5
- 230000021164 cell adhesion Effects 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 230000004154 complement system Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000003925 fat Substances 0.000 description 5
- 235000013373 food additive Nutrition 0.000 description 5
- 239000002778 food additive Substances 0.000 description 5
- 208000027866 inflammatory disease Diseases 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 210000003556 vascular endothelial cell Anatomy 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 206010018910 Haemolysis Diseases 0.000 description 4
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 4
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 230000008588 hemolysis Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 230000001338 necrotic effect Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 101100346152 Drosophila melanogaster modSP gene Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 101150013552 LDLR gene Proteins 0.000 description 3
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 244000273928 Zingiber officinale Species 0.000 description 3
- 235000006886 Zingiber officinale Nutrition 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- FTOAOBMCPZCFFF-UHFFFAOYSA-N barbitone sodium Natural products CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 235000008397 ginger Nutrition 0.000 description 3
- 239000002044 hexane fraction Substances 0.000 description 3
- 239000005550 inflammation mediator Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000015206 pear juice Nutrition 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- DANYIYRPLHHOCZ-UHFFFAOYSA-N 5,7-dihydroxy-4'-methoxyflavone Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 DANYIYRPLHHOCZ-UHFFFAOYSA-N 0.000 description 2
- 235000005078 Chaenomeles speciosa Nutrition 0.000 description 2
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 244000251905 Pseudocydonia sinensis Species 0.000 description 2
- 235000017831 Pseudocydonia sinensis Nutrition 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 208000038016 acute inflammation Diseases 0.000 description 2
- 230000006022 acute inflammation Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 210000004618 arterial endothelial cell Anatomy 0.000 description 2
- 229960002319 barbital Drugs 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 150000001747 carotenoids Chemical class 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000017803 cinnamon Nutrition 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 229930004069 diterpene Natural products 0.000 description 2
- 125000000567 diterpene group Chemical group 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 235000019674 grape juice Nutrition 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004941 influx Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical group C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 229930015704 phenylpropanoid Natural products 0.000 description 2
- 125000001474 phenylpropanoid group Chemical group 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000003371 toe Anatomy 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108010089414 Anaphylatoxins Proteins 0.000 description 1
- 240000001810 Angelica gigas Species 0.000 description 1
- 235000018865 Angelica gigas Nutrition 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 102000013918 Apolipoproteins E Human genes 0.000 description 1
- 108010025628 Apolipoproteins E Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241001275944 Misgurnus anguillicaudatus Species 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- MZNYWPRCVDMOJG-UHFFFAOYSA-N N-(1-naphthyl)ethylenediamine dihydrochloride Chemical compound [Cl-].[Cl-].C1=CC=C2C([NH2+]CC[NH3+])=CC=CC2=C1 MZNYWPRCVDMOJG-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 102100035558 Zinc finger protein GLI2 Human genes 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 235000009962 acacetin Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 125000005233 alkylalcohol group Chemical group 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 229960000796 barbital sodium Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 235000020230 cinnamon extract Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940002508 ginger extract Drugs 0.000 description 1
- 235000020708 ginger extract Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 239000006049 herbal material Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000011645 inflammation animal model Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000077 insect repellent Substances 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000013435 necrotic lesion Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000018052 penile erection Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000007981 phosphate-citrate buffer Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940069774 quince extract Drugs 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000002784 sclerotic effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 210000003291 sinus of valsalva Anatomy 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/532—Agastache, e.g. giant hyssop
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20010009977 | 2001-02-27 | ||
| PCT/KR2001/002224 WO2002074320A1 (en) | 2001-02-27 | 2001-12-20 | Agastache rugosa extract and composition containing tilianin isolated and purified from said extract having anti-inflammatory activity and anti-atherogenic activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004521933A JP2004521933A (ja) | 2004-07-22 |
| JP2004521933A5 JP2004521933A5 (https=) | 2005-05-26 |
| JP4091436B2 true JP4091436B2 (ja) | 2008-05-28 |
Family
ID=19706307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002573027A Expired - Fee Related JP4091436B2 (ja) | 2001-02-27 | 2001-12-20 | 抗炎症活性および抗アテローム生成活性を示すカワミドリ抽出物およびそれから単離され、精製されたチリアニンを含有する組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20040071792A1 (https=) |
| EP (1) | EP1363648B8 (https=) |
| JP (1) | JP4091436B2 (https=) |
| KR (1) | KR100447948B1 (https=) |
| CN (1) | CN100376255C (https=) |
| CA (1) | CA2439430C (https=) |
| DE (1) | DE60124591T2 (https=) |
| WO (1) | WO2002074320A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060003030A1 (en) * | 2004-07-01 | 2006-01-05 | Lin Chun-Ying | Essential oils for treating and/ or preventing allergic disease |
| KR100807645B1 (ko) * | 2006-10-17 | 2008-02-28 | 주식회사 유니젠 | 위장질환 치료 및 예방용 조성물 및 그의 제조방법 |
| KR100851489B1 (ko) * | 2006-11-30 | 2008-08-08 | (주)아모레퍼시픽 | 틸리아닌( ｔｉｌｉａｎｉｎ) 또는아카세틴(ａｃａｃｅｔｉｎ)을 유효성분으로 함유하는화장료 조성물 |
| DE202008011721U1 (de) * | 2008-09-03 | 2008-12-24 | American Phoenix Biotech Inc., Hacienda Heights | Pflanzliche Zusammensetzung zur Behandlung von Krebs |
| KR101540310B1 (ko) * | 2013-08-07 | 2015-07-30 | 건국대학교 산학협력단 | 방아풀 추출물을 함유하는 신경 염증 예방 및 치료용 조성물, 그리고 방아풀 추출물 추출 방법 |
| CN107429226A (zh) * | 2015-01-06 | 2017-12-01 | 株式会社露太利温 | luterion及其分离和培养方法 |
| PL412214A1 (pl) | 2015-05-04 | 2016-11-07 | Biovico Spółka Z Ograniczoną Odpowiedzialnością | Kompozycja roślinna o właściwościach przeciwzapalnych, przeciwalergicznych i/lub przeciwastmatycznych oraz jej zastosowanie |
| KR102049875B1 (ko) | 2018-06-29 | 2019-11-28 | 충북대학교 산학협력단 | 에키나세아 배양근 유래 신규 화합물 및 이의 항염증 용도 |
| CN111171094B (zh) * | 2018-11-13 | 2023-06-16 | 上海医药工业研究院有限公司 | 一种香清兰苷中间体及其制备方法和应用 |
| US12472221B2 (en) * | 2019-05-23 | 2025-11-18 | Korea Institute Of Oriental Medicine | Composition for inhibiting osteoclasts containing agastache rugosa extract as active ingredient, and use thereof |
| KR102339923B1 (ko) * | 2019-11-12 | 2021-12-20 | 한국한의학연구원 | 혈행 개선용 식치제호탕 조성물 |
| KR102300732B1 (ko) * | 2020-11-11 | 2021-09-14 | 주식회사 제이에스무역 | 난황유 및 배초향 줄기세포를 함유하는 항산화, 미백, 항주름 또는 항염증용 조성물 |
| JP2025143197A (ja) * | 2024-03-18 | 2025-10-01 | ペガヴィジョン コーポレーション | 皮膚バリア強化及び抗炎症用のカワミドリエキソソーム組成物及びその用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3831196A1 (de) * | 1988-09-14 | 1990-03-22 | Bosch Gmbh Robert | Elektromagnetisch betaetigbares ventil |
| CN1060772A (zh) * | 1991-10-30 | 1992-05-06 | 阳山县食品厂 | 一种藿香姜计陈皮的生产工艺 |
| CN1057447C (zh) * | 1993-01-22 | 2000-10-18 | 马军营 | 一种治疗小儿腹泻的口服液 |
| CN1117388A (zh) * | 1994-08-24 | 1996-02-28 | 东营市面粉厂 | 复方柴胡擦剂 |
| JPH08176002A (ja) * | 1994-12-27 | 1996-07-09 | Kao Corp | 細胞接着抑制剤 |
| KR970007366A (ko) * | 1995-07-31 | 1997-02-21 | 고제섭 | 압축단자 접촉저항 측정장치 및 그 방법 |
| CN1151881A (zh) * | 1995-12-01 | 1997-06-18 | 陶周行 | 一种阴道冲洗保留剂及其制备工艺与使用方法 |
| CA2272540C (en) * | 1996-09-27 | 2009-09-01 | Takeshi Karita | Anti-oxidizing composition for scavenging free radicals, pharmaceutical composition comprising the same, and process for preparing the same |
| US5776462A (en) * | 1996-12-10 | 1998-07-07 | Sage R&D, A Partnership | Pogostemon cablin extract for inhibiting H. influenzae adhesion and treating otitis media or sore throat |
| KR100232053B1 (ko) * | 1997-04-22 | 1999-12-01 | 김동태 | DPPH(1,1-diphenyl-2-picrylhydrazyl)를 이용한 항산화물질의 분석방법 |
| JP4231559B2 (ja) * | 1997-04-23 | 2009-03-04 | オリザ油化株式会社 | リポキシゲナーゼ阻害剤 |
| KR100215400B1 (ko) * | 1997-05-27 | 1999-08-16 | 김진수 | 건강보조식품용 유중수적형 영양음료 및 그 제조방법 |
| KR100309071B1 (ko) * | 1998-09-02 | 2001-12-17 | 성재갑 | 콜라겐합성촉진제를함유한피부용조성물 |
| KR100341798B1 (ko) * | 1999-08-04 | 2002-06-26 | 대한민국 (관리청:특허청장, 승계청:농촌진흥청장) | 방아잎으로부터 로즈마린산을 분리하는 방법 |
| WO2001045725A2 (en) * | 1999-12-23 | 2001-06-28 | Ancile Pharmaceuticals, Inc. | Treatment for inflammatory bowel disease (ibd) and related conditions |
| KR100376306B1 (ko) * | 2000-08-07 | 2003-03-17 | 한완석 | 혈액순환 촉진용 건강식품 조성물 |
| CN1126453C (zh) * | 2000-08-09 | 2003-11-05 | 郭兴华 | 天然抗菌组合物及其应用 |
| CN1282537A (zh) * | 2000-08-22 | 2001-02-07 | 张益� | 一种藿香饮料 |
-
2001
- 2001-07-03 KR KR10-2001-0039574A patent/KR100447948B1/ko not_active Expired - Fee Related
- 2001-12-20 US US10/469,025 patent/US20040071792A1/en not_active Abandoned
- 2001-12-20 WO PCT/KR2001/002224 patent/WO2002074320A1/en not_active Ceased
- 2001-12-20 CN CNB018230695A patent/CN100376255C/zh not_active Expired - Fee Related
- 2001-12-20 DE DE60124591T patent/DE60124591T2/de not_active Expired - Lifetime
- 2001-12-20 CA CA2439430A patent/CA2439430C/en not_active Expired - Fee Related
- 2001-12-20 JP JP2002573027A patent/JP4091436B2/ja not_active Expired - Fee Related
- 2001-12-20 EP EP01274005A patent/EP1363648B8/en not_active Expired - Lifetime
-
2007
- 2007-05-23 US US11/802,527 patent/US7534456B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2439430A1 (en) | 2002-09-26 |
| US7534456B2 (en) | 2009-05-19 |
| CN100376255C (zh) | 2008-03-26 |
| EP1363648B1 (en) | 2006-11-15 |
| CN1518454A (zh) | 2004-08-04 |
| US20080081081A1 (en) | 2008-04-03 |
| WO2002074320A1 (en) | 2002-09-26 |
| DE60124591T2 (de) | 2007-09-06 |
| EP1363648A1 (en) | 2003-11-26 |
| EP1363648B8 (en) | 2007-04-25 |
| KR100447948B1 (ko) | 2004-09-08 |
| EP1363648A4 (en) | 2005-02-09 |
| KR20020070062A (ko) | 2002-09-05 |
| CA2439430C (en) | 2010-06-22 |
| DE60124591D1 (de) | 2006-12-28 |
| US20040071792A1 (en) | 2004-04-15 |
| JP2004521933A (ja) | 2004-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7534456B2 (en) | Agastache rugosa extract and composition containing tilianin isolated and purified from said extract having anti-inflammatory activity and anti-atherogenic activity | |
| KR101715274B1 (ko) | 감국 추출물 또는 분획물을 유효성분으로 포함하는 염증 질환 예방, 개선 또는 치료용 조성물 | |
| CN107397830A (zh) | 番茄提取物用作抗高血压剂的用途以及制造水溶性无糖番茄提取物的方法 | |
| Wallace et al. | Anthocyanins in cardiovascular disease prevention | |
| KR101667224B1 (ko) | 혈전성 질병을 방지하기 위한 약학 조성물 및 그의 제조 및 용도 | |
| CN111956738A (zh) | 一种黄精提取物及其制备方法和用途 | |
| KR20180065001A (ko) | 비가열 참깨박 추출물을 유효성분으로 포함하는 항염증 조성물 | |
| EA014070B1 (ru) | Применение растительной композиции для лечения воспалительных нарушений | |
| WO2019203338A1 (ja) | ターメロノールａ及び／又はターメロノールｂを含有する組成物 | |
| KR101269590B1 (ko) | 애기땅빈대 추출물을 유효성분으로 포함하는 염증 질환 또는 알러지 질환의 예방 또는 치료용 조성물 | |
| KR100460439B1 (ko) | 배초향 추출물이 함유된 식품첨가제 | |
| CN101588810A (zh) | 用于治疗和预防炎性疾病的包括络石藤和日本鹿蹄草提取物的组合物 | |
| JP2005502597A (ja) | 韓国産エゾウコギ抽出物、これに由来する抽出蛋白質及び粗蛋白多糖類、そしてこれを有効成分とする免疫調節用組成物及びその用途 | |
| TW202416945A (zh) | 用於治療發炎之組合療法 | |
| KR20070108291A (ko) | 알레르기 증상의 예방 또는 개선 작용을 갖는 음식물 및당해 음식물의 제조방법 | |
| CN109045107B (zh) | 一种治疗类风湿关节炎的药物及制备方法 | |
| Nwankwo et al. | Antimalarial potential of ethanol extract, and anti-inflammatory properties of flavonoid-, terpenoid-, and alkaloid-rich fractions of Sida linifolia L. | |
| CN101376624A (zh) | 用于护肝的牛樟芝环己烯酮化合物 | |
| JP2001258505A (ja) | 食品組成物 | |
| Enechi et al. | Insights on the anti-inflammatory mechanism of the polyphenolic rich fraction of Glyphaea brevis (Spreng.) Monachino (Tiliaceae) leaves | |
| JPS62255433A (ja) | 血中の中性脂肪濃度正常化用組成物 | |
| KR20130046094A (ko) | 어저귀 추출물을 포함하는 염증성질환 예방 또는 치료용 의약 조성물 | |
| KR20150022716A (ko) | 다우리놀 화합물을 유효성분으로 포함하는 면역질환의 예방 및 치료용 조성물 | |
| Liu | Therapeutic Effects of Dietary Vesicle-Like Nanoparticles on NLRP3 Inflammasome-Mediated Inflammatory Diseases | |
| JP2022008715A (ja) | ウキクサ抽出物を有効成分として含む肝疾患の予防または治療用組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071001 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071228 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080204 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080228 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4091436 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110307 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110307 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120307 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130307 Year of fee payment: 5 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140307 Year of fee payment: 6 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |